Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Rev Esp Enferm Dig ; 2024 Apr 30.
Article in English | MEDLINE | ID: mdl-38685898

ABSTRACT

33-year-old woman, previously hospitalized for self-limited migratory bile duct strictures, presented with jaundice three months after giving birth. Blood analysis revealed elevated levels of aspartate aminotransaminase 1064U/L, alanine aminotransaminase 1097U/L, gamma-glutamyl transferase 194U/L, alkaline phosphatase 284U/L, bilirubin 27mg/dL and prothrombin time of 19.3s. Magnetic resonance-cholangiopancreatography revealed intrahepatic bile duct dilation with a stenosis in the common hepatic duct, not detected on endoscopic retrograde cholangiopancreatography. Additionally, diffuse signal abnormalities were observed in the liver parenchyma on T2 sequences. An early liver biopsy showed moderate-severe interface hepatitis with IgG4-positive plasma cell infiltration (IgG4-PPC) of 8-20cells/HPF, hepatocellular ballooning and focal rosette formation, yielding 6 points of the simplified-score for autoimmune hepatitis and treatment with methylprednisolone was initiated. Despite treatment, there was no improvement after two weeks and the patient received rituximab as a rescue treatment, but three days later, developed candida sepsis with rapid progression to multiorgan failure, ultimately resulting in death.

3.
Med Clin (Barc) ; 162(3): 141, 2024 02 09.
Article in English, Spanish | MEDLINE | ID: mdl-38040572
4.
Commun Biol ; 6(1): 891, 2023 08 30.
Article in English | MEDLINE | ID: mdl-37648791

ABSTRACT

Fundamental movement patterns require continuous skeletal muscle coordination, where muscle fibers with different timing of activation synchronize their dynamics across muscles with distinct functions. It is unknown how muscle fibers integrate as a network to generate and fine tune movements. We investigate how distinct muscle fiber types synchronize across arm and chest muscles, and respond to fatigue during maximal push-up exercise. We uncover that a complex inter-muscular network of muscle fiber cross-frequency interactions underlies push-up movements. The network exhibits hierarchical organization (sub-networks/modules) with specific links strength stratification profile, reflecting distinct functions of muscles involved in push-up movements. We find network reorganization with fatigue where network modules follow distinct phase-space trajectories reflecting their functional role and adaptation to fatigue. Consistent with earlier observations for squat movements under same protocol, our findings point to general principles of inter-muscular coordination for fundamental movements, and open a new area of research, Network Physiology of Exercise.


Subject(s)
Movement , Muscle Fibers, Skeletal , Humans , Muscle, Skeletal , Posture , Muscle Fatigue
5.
Med. clín (Ed. impr.) ; 160(7): 310-317, abril 2023. tab, ilus
Article in Spanish | IBECS | ID: ibc-218094

ABSTRACT

La granulomatosis eosinofílica con poliangeítis (GEPA) es una vasculitis sistémica que se caracteriza por la presencia de asma asociado a eosinofilia, infiltración eosinofílica en diferentes órganos y vasculitis de vasos de pequeño y mediano calibre. Aunque clasificada como vasculitis asociadas a anticuerpos anticitoplasma de neutrófilos (ANCA), estos se presentan en menos de la mitad de los pacientes. Es una enfermedad infrecuente, que aparece típicamente en pacientes con asma y afectando a múltiples órganos como pulmón, piel y sistema nervioso periférico. Su tratamiento se ha basado en el uso de glucocorticoides e inmunosupresores. En los últimos años, se ha avanzado en el conocimiento de la fisiopatología, en el tratamiento con la inclusión de fármacos biológicos, se han revisado los criterios de clasificación y se han publicado nuevas recomendaciones terapéuticas. (AU)


Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by the presence of asthma associated with eosinophilia, eosinophilic infiltration of different organs, and vasculitis of small and medium-sized vessels. Although classified as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, it occurs in less than half of the patients. The disease is infrequent, typically appearing in patients with asthma and affecting multiple organs such as lung, skin and peripheral nervous system. Treatment has been based on the use of glucocorticoids and immunosuppressants. In recent years, progress has been made in the knowledge of the pathophysiology, in treatment with the inclusion of biologic agents, the classification criteria have been revised and new therapeutic recommendations have been published. (AU)


Subject(s)
Humans , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications , Churg-Strauss Syndrome/complications , Churg-Strauss Syndrome/diagnosis , Churg-Strauss Syndrome/drug therapy , Granulomatosis with Polyangiitis/complications , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/drug therapy , Eosinophilia/complications , Eosinophilia/etiology
6.
Med Clin (Barc) ; 160(7): 310-317, 2023 04 06.
Article in English, Spanish | MEDLINE | ID: mdl-36774291

ABSTRACT

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by the presence of asthma associated with eosinophilia, eosinophilic infiltration of different organs, and vasculitis of small and medium-sized vessels. Although classified as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, it occurs in less than half of the patients. The disease is infrequent, typically appearing in patients with asthma and affecting multiple organs such as lung, skin and peripheral nervous system. Treatment has been based on the use of glucocorticoids and immunosuppressants. In recent years, progress has been made in the knowledge of the pathophysiology, in treatment with the inclusion of biologic agents, the classification criteria have been revised and new therapeutic recommendations have been published.


Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Asthma , Churg-Strauss Syndrome , Eosinophilia , Granulomatosis with Polyangiitis , Humans , Granulomatosis with Polyangiitis/complications , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/drug therapy , Churg-Strauss Syndrome/complications , Churg-Strauss Syndrome/diagnosis , Churg-Strauss Syndrome/drug therapy , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications , Eosinophilia/etiology , Eosinophilia/complications , Antibodies, Antineutrophil Cytoplasmic , Asthma/complications
7.
Article in English | MEDLINE | ID: mdl-36429489

ABSTRACT

Obesity, diabetes mellitus, and cardiovascular risk are real challenges in systemic lupus erythematosus (SLE) clinical practice and research. The evidence of the burden of these health problems in SLE patients is determined by the methods used to assess them. Therefore, the aim of this scoping review is to map current approaches in assessing obesity, diabetes mellitus, and cardiovascular risk burden in SLE patients and to identify existing knowledge gaps in this field. This rapid scoping review was conducted according to the Joanna Briggs Institute methodology and identified 274 articles, of which 73 were included. Most studies were conducted at European institutions and patients were recruited from specialist hospital clinics, the majority of whom were women. The burden of obesity and diabetes mellitus for SLE patients was assessed mainly in terms of prevalence, impact on disease activity, and cardiometabolic risk. The burden of cardiovascular risk was assessed using multiple approaches, mainly imaging and laboratory methods, and risk factor-based scores, although there is great heterogeneity and uncertainty between the methods used. This review highlights the importance of improving and standardizing the approach to obesity, diabetes, and cardiovascular risk in SLE patients through a holistic assessment that includes lifestyle, clinical, biological, and social aspects.


Subject(s)
Cardiovascular Diseases , Diabetes Mellitus , Lupus Erythematosus, Systemic , Humans , Female , Male , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Risk Factors , Diabetes Mellitus/epidemiology , Heart Disease Risk Factors , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/epidemiology , Obesity/complications , Obesity/epidemiology
8.
Ther Adv Musculoskelet Dis ; 13: 1759720X211020917, 2021.
Article in English | MEDLINE | ID: mdl-34211589

ABSTRACT

OBJECTIVE: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. METHODS: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. RESULTS: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZCOMBO were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. CONCLUSION: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

9.
J Clin Med ; 10(9)2021 Apr 23.
Article in English | MEDLINE | ID: mdl-33922777

ABSTRACT

(1) Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. (2) Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. (3) Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. (4) Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects.

10.
Rheumatol Int ; 41(8): 1531-1539, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33484332

ABSTRACT

Eosinophilic fasciitis (EF) is characterized by symmetrical thickening of subcutaneous muscular fascia, causing skin induration with wrinkles and prominent hair follicles: the classic peau d'orange. Eosinophilia is a characteristic-albeit not universal-finding. We present the case of a 43-year-old pregnant woman diagnosed with EF during pregnancy who had extensive cutaneous involvement and severe functional repercussions, including worsening of lung function and intrauterine growth restriction as a possible complication. Treatment with prednisone was initiated during gestation and it was necessary to increase the dose. After delivery, methotrexate treatment was initiated and the corticosteroid dose progressively decreased, with progressive worsening in the torso and abdomen and secondary dyspnea due to thoracic pressure. Treatment with infliximab was then initiated, with favorable progress, though residual ankle and tarsal joint stiffness and significant muscular atrophy in the limbs continued. The triggering factor of EF was not identified. In a systematic search of the medical literature, three cases of EF in pregnant woman without clear triggers were found. Interestingly, all three cases progressed favorably with steroid treatment. Apart from this case, there are only seven published cases of infliximab use in the literature, all with moderate or complete response. Infliximab could be an option for corticosteroid-dependent EF with no response to other options.


Subject(s)
Antirheumatic Agents/therapeutic use , Eosinophilia/drug therapy , Fasciitis/drug therapy , Infliximab/therapeutic use , Pregnancy Complications/drug therapy , Adult , Female , Humans , Prednisolone/administration & dosage , Pregnancy , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...